This page shows the latest Forty Seven news and features for those working in and with pharma, biotech and healthcare.
Gilead also noted net loss for the second quarter could be also be attributed to charges related to its recent acquisition of immuno-oncology biotech Forty Seven.
In March, Gilead also signed a $4.9bn deal to acquire Forty Seven, a company that specialises in cancer immunotherapies targeting the CD47 immune checkpoint.
That includes a $4.9bn deal signed in March to acquire Forty Seven, a company that specialises in cancer immunotherapies targeting the CD47 immune checkpoint.
Gilead is paying $95.50 per share for Forty Seven and its lead drug magrolimab, a 60% premium to the biotech’s closing share price on Friday, although shares in the ... Forty Seven is also testing the drug in patients with non-Hodgkin's lymphoma,
Innovent is facing some well-positioned competition in the CD47 space. A US biotech – Stanford University spinout Forty Seven – is advancing a CD47-targeting antibody called Hu5F9-G4 in mid-stage
varlilumab, Forty Seven’s anti-CD47 drug Hu5F9-G4 and CD122-biased agonist NKTR-214 from Nektar, to name just a few.
More from news
Approximately 1 fully matching, plus 8 partially matching documents found.
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....